ECSP10010709A - Nuevas piridin-2-onas y piridazin-3-onas sustituidas - Google Patents
Nuevas piridin-2-onas y piridazin-3-onas sustituidasInfo
- Publication number
- ECSP10010709A ECSP10010709A EC2010010709A ECSP10010709A ECSP10010709A EC SP10010709 A ECSP10010709 A EC SP10010709A EC 2010010709 A EC2010010709 A EC 2010010709A EC SP10010709 A ECSP10010709 A EC SP10010709A EC SP10010709 A ECSP10010709 A EC SP10010709A
- Authority
- EC
- Ecuador
- Prior art keywords
- btk
- compounds
- piridazin
- piridin
- onas
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Vascular Medicine (AREA)
- Psychology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
Abstract
Esta solicitud se refiere a derivados de 5-fenil-1H-piridin-2-ona y 6-fenil-2H-piridazin-3-ona que se ajustan a las fórmulas genéricas I-IV:(I) (II) (III) (IV)en el que variables R, X, Y1, Y2, Y2', Y3, Y4, n y m tienen los significados aquí descritos, dichos derivados inhiben la Btk. Los compuestos aquí descritos son útiles para modular la actividad de la Btk y tratar enfermedades asociadas con una actividad excesiva de la Btk. Los compuestos son útiles además para tratar enfermedades inflamatorias y autoinmunes asociadas con una proliferación aberrante de las células B, por ejemplo la artritis reumatoide. Se describen también composiciones que contienen los compuestos de las fórmulas I-IV y por lo menos un vehículo, diluyente o excipiente.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7527708P | 2008-06-24 | 2008-06-24 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP10010709A true ECSP10010709A (es) | 2011-01-31 |
Family
ID=40972952
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2010010709A ECSP10010709A (es) | 2008-06-24 | 2010-12-23 | Nuevas piridin-2-onas y piridazin-3-onas sustituidas |
Country Status (25)
| Country | Link |
|---|---|
| US (4) | US7902194B2 (es) |
| EP (1) | EP2297142B1 (es) |
| JP (1) | JP5536049B2 (es) |
| KR (1) | KR101299867B1 (es) |
| CN (3) | CN102066366B (es) |
| AR (1) | AR072272A1 (es) |
| AU (1) | AU2009264400B2 (es) |
| BR (1) | BRPI0914657A2 (es) |
| CA (1) | CA2728016C (es) |
| CL (1) | CL2010001483A1 (es) |
| CO (1) | CO6382183A2 (es) |
| CR (1) | CR11815A (es) |
| EC (1) | ECSP10010709A (es) |
| ES (1) | ES2552320T3 (es) |
| HK (2) | HK1152940A1 (es) |
| IL (1) | IL209141A0 (es) |
| MA (1) | MA32487B1 (es) |
| MX (1) | MX2010013191A (es) |
| NZ (2) | NZ588819A (es) |
| PE (1) | PE20100851A1 (es) |
| RU (1) | RU2500680C2 (es) |
| TW (1) | TWI396537B (es) |
| UA (1) | UA103327C2 (es) |
| WO (1) | WO2009156284A1 (es) |
| ZA (1) | ZA201007816B (es) |
Families Citing this family (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200900396A (en) * | 2007-04-10 | 2009-01-01 | Kudos Pharm Ltd | Phthalazinone derivatives |
| PE20110164A1 (es) * | 2008-07-02 | 2011-03-28 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de quinasa |
| US8299077B2 (en) * | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| CA2748414A1 (en) * | 2009-04-24 | 2010-10-28 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| AR085683A1 (es) | 2010-05-07 | 2013-10-23 | Gilead Connecticut Inc | Compuestos de piridona y aza-piridona y metodos de uso |
| AR082590A1 (es) * | 2010-08-12 | 2012-12-19 | Hoffmann La Roche | Inhibidores de la tirosina-quinasa de bruton |
| KR20180031823A (ko) | 2010-09-01 | 2018-03-28 | 질레드 코네티컷 인코포레이티드 | 피리다지논, 그의 제조 방법 및 사용 방법 |
| CA2841801A1 (en) * | 2011-08-17 | 2013-02-21 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| AR088642A1 (es) | 2011-11-03 | 2014-06-25 | Genentech Inc | Compuestos de piperazina alquilados |
| US8669251B2 (en) * | 2011-11-03 | 2014-03-11 | Genentech, Inc. | 8-fluorophthalazin-1(2H)-one compounds |
| WO2013067260A1 (en) * | 2011-11-03 | 2013-05-10 | Genentech, Inc. | Bicyclic piperazine compounds |
| EP2788347A1 (en) | 2011-12-09 | 2014-10-15 | F.Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| US9365566B2 (en) | 2012-03-27 | 2016-06-14 | Takeda Pharmaceutical Company Limited | Cinnoline derivatives |
| MX2015001081A (es) | 2012-07-24 | 2015-10-14 | Pharmacyclics Inc | Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk). |
| NZ703607A (en) | 2012-08-10 | 2018-02-23 | Boehringer Ingelheim Int | Heteroaromatic compounds as bruton’s tyrosine kinase (btk) inhibitors |
| US9499548B2 (en) * | 2012-09-13 | 2016-11-22 | Hoffmann-La Roche Inc. | Inhibitors of bruton's tyrosine kinase |
| EP2920162B1 (en) * | 2012-11-16 | 2017-04-19 | F. Hoffmann-La Roche AG | Inhibitors of bruton's tyrosine kinase |
| US9556147B2 (en) | 2013-03-05 | 2017-01-31 | Hoffmann-La Inc. | Inhibitors of bruton's tyrosine kinase |
| JO3377B1 (ar) | 2013-03-11 | 2019-03-13 | Takeda Pharmaceuticals Co | مشتقات بيريدينيل وبيريدينيل مندمج |
| CN104177338B (zh) * | 2013-05-22 | 2018-04-03 | 南京勇山生物科技有限公司 | 一类布鲁顿激酶抑制剂 |
| BR112015029972A2 (pt) * | 2013-07-03 | 2017-07-25 | Hoffmann La Roche | composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto |
| US9993460B2 (en) | 2013-07-26 | 2018-06-12 | Race Oncology Ltd. | Compositions to improve the therapeutic benefit of bisantrene and analogs and derivatives thereof |
| US9382256B2 (en) | 2013-07-30 | 2016-07-05 | Gilead Connecticut, Inc. | Formulation of Syk inhibitors |
| US9657023B2 (en) | 2013-07-30 | 2017-05-23 | Gilead Connecticut, Inc. | Polymorph of Syk inhibitors |
| US9260415B2 (en) | 2013-12-05 | 2016-02-16 | Genentech, Inc. | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| CA2931189C (en) * | 2013-12-13 | 2017-09-26 | F. Hoffmann-La Roche Ag | Inhibitors of bruton's tyrosine kinase |
| UY35898A (es) | 2013-12-23 | 2015-07-31 | Gilead Sciences Inc | ?compuestos inhibidores de syk y composiciones que los comprenden?. |
| TW201702218A (zh) | 2014-12-12 | 2017-01-16 | 美國杰克森實驗室 | 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法 |
| WO2017123695A1 (en) * | 2016-01-13 | 2017-07-20 | Boehringer Ingelheim International Gmbh | Isoquinolones as btk inhibitors |
| US20190105407A1 (en) | 2016-03-31 | 2019-04-11 | Takeda Pharmaceutical Company Limited | Isoquinolinyl triazolone complexes |
| AU2017326558B2 (en) | 2016-09-19 | 2022-01-06 | Mei Pharma, Inc. | Combination therapy |
| WO2019040298A1 (en) | 2017-08-25 | 2019-02-28 | Gilead Sciences, Inc. | SYK INHIBITORY POLYMORPHS |
| JP2021506978A (ja) | 2017-12-22 | 2021-02-22 | ラヴェンナ ファーマシューティカルズ，インコーポレイテッド | ホスファチジルイノシトールリン酸キナーゼ阻害剤としてのアミノピリジン誘導体 |
| CN113950479A (zh) | 2019-02-22 | 2022-01-18 | 克洛诺斯生物股份有限公司 | 作为syk抑制剂的缩合吡嗪的固体形式 |
| BR112021018168B1 (pt) | 2019-03-21 | 2023-11-28 | Onxeo | Composição farmacêutica, combinação e kit compreendendo uma molécula dbait e um inibidor de quinase para o tratamento de câncer |
| TW202112767A (zh) | 2019-06-17 | 2021-04-01 | 美商佩特拉製藥公司 | 作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物 |
| AU2020378630A1 (en) | 2019-11-08 | 2022-05-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for the treatment of cancers that have acquired resistance to kinase inhibitors |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6255303B1 (en) * | 1998-03-14 | 2001-07-03 | Byk Gulden Lomberg Chemische Fabrik Gmbh | Phthalazinone PDE III/IV inhibitors |
| CZ20014244A3 (cs) * | 1999-06-03 | 2002-07-17 | Knoll Gmbh | Benzotiazinonové a benzoxazinonové sloučeniny |
| CA2387351C (en) * | 1999-10-19 | 2009-09-08 | Merck & Co., Inc. | Indole derivatives as tyrosine kinase inhibitors |
| AU2003270489A1 (en) | 2002-09-09 | 2004-03-29 | Cellular Genomics, Inc. | 6-ARYL-IMIDAZO(1,2-a)PYRAZIN-8-YLAMINES, METHOD OF MAKING, AND METHOD OF USE THEREOF |
| US7405295B2 (en) | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| MX2007011041A (es) * | 2005-03-10 | 2008-02-22 | Cgi Pharmaceuticals Inc | Ciertas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas. |
| WO2006124731A2 (en) | 2005-05-12 | 2006-11-23 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
| CN101282975A (zh) | 2005-08-09 | 2008-10-08 | Irm责任有限公司 | 作为蛋白激酶抑制剂的化合物和组合物 |
| CA2620269A1 (en) * | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3,5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| WO2007027729A1 (en) | 2005-08-29 | 2007-03-08 | Vertex Pharmaceuticals Incorporated | 3, 5-disubstituted pyrid-2-ones useful as inhibitors of tec family of non-receptor tyrosine kinases |
| ES2361338T3 (es) | 2005-08-29 | 2011-06-16 | Vertex Pharmaceuticals Incorporated | Pirid-2-onas 3,5-disustituidas útiles como inhibidores de la familia tec de tirosina quinasas no ligadas a receptor. |
| CN101405001A (zh) * | 2006-03-20 | 2009-04-08 | 霍夫曼-拉罗奇有限公司 | 抑制btk和syk蛋白质激酶的方法 |
| AU2007254491A1 (en) * | 2006-05-15 | 2007-11-29 | Irm Llc | Compositions and methods for FGF receptor kinases inhibitors |
| PE20081370A1 (es) | 2006-09-11 | 2008-11-28 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| US7838523B2 (en) * | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| PE20080839A1 (es) | 2006-09-11 | 2008-08-23 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas |
| WO2008033858A2 (en) | 2006-09-11 | 2008-03-20 | Cgi Pharmaceuticals, Inc. | Kinase inhibitors, and methods of using and identifying kinase inhibitors |
| CL2008002793A1 (es) | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
| CA2701275C (en) * | 2007-10-23 | 2016-06-21 | F. Hoffmann-La Roche Ag | Kinase inhibitors |
| EP2229390B1 (en) | 2007-12-14 | 2014-04-09 | F. Hoffmann-La Roche AG | Novel imidazoý1,2-a¨pyridine and imidazoý1,2-b¨pyridazine derivatives |
| BRPI0907915A2 (pt) | 2008-02-05 | 2015-07-28 | Hoffmann La Rocha Ag F | Piridinonas e piridazinonas |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
-
2009
- 2009-06-15 CN CN200980123734.6A patent/CN102066366B/zh not_active Expired - Fee Related
- 2009-06-15 ES ES09769133.1T patent/ES2552320T3/es active Active
- 2009-06-15 CN CN201310740898.1A patent/CN103709148B/zh not_active Expired - Fee Related
- 2009-06-15 JP JP2011514004A patent/JP5536049B2/ja not_active Expired - Fee Related
- 2009-06-15 NZ NZ588819A patent/NZ588819A/xx not_active IP Right Cessation
- 2009-06-15 CA CA2728016A patent/CA2728016C/en not_active Expired - Fee Related
- 2009-06-15 UA UAA201100578A patent/UA103327C2/ru unknown
- 2009-06-15 RU RU2011101774/04A patent/RU2500680C2/ru not_active IP Right Cessation
- 2009-06-15 WO PCT/EP2009/057320 patent/WO2009156284A1/en active Application Filing
- 2009-06-15 KR KR1020107029040A patent/KR101299867B1/ko not_active IP Right Cessation
- 2009-06-15 MX MX2010013191A patent/MX2010013191A/es active IP Right Grant
- 2009-06-15 EP EP09769133.1A patent/EP2297142B1/en active Active
- 2009-06-15 BR BRPI0914657A patent/BRPI0914657A2/pt not_active IP Right Cessation
- 2009-06-15 AU AU2009264400A patent/AU2009264400B2/en not_active Expired - Fee Related
- 2009-06-15 PE PE2010001046A patent/PE20100851A1/es not_active Application Discontinuation
- 2009-06-15 CN CN201310343743.4A patent/CN103408533B/zh not_active Expired - Fee Related
- 2009-06-15 NZ NZ601700A patent/NZ601700A/xx not_active IP Right Cessation
- 2009-06-22 AR ARP090102276A patent/AR072272A1/es not_active Application Discontinuation
- 2009-06-23 TW TW098121074A patent/TWI396537B/zh not_active IP Right Cessation
- 2009-06-24 US US12/456,911 patent/US7902194B2/en not_active Expired - Fee Related
-
2010
- 2010-10-25 CO CO10132213A patent/CO6382183A2/es active IP Right Grant
- 2010-11-01 ZA ZA2010/07816A patent/ZA201007816B/en unknown
- 2010-11-04 IL IL209141A patent/IL209141A0/en unknown
- 2010-11-25 CR CR11815A patent/CR11815A/es not_active Application Discontinuation
- 2010-12-20 CL CL2010001483A patent/CL2010001483A1/es unknown
- 2010-12-23 EC EC2010010709A patent/ECSP10010709A/es unknown
-
2011
- 2011-01-10 US US12/987,187 patent/US8124604B2/en not_active Expired - Fee Related
- 2011-01-18 MA MA33534A patent/MA32487B1/fr unknown
- 2011-07-08 HK HK11107060.7A patent/HK1152940A1/xx not_active IP Right Cessation
-
2012
- 2012-01-26 US US13/358,557 patent/US8618098B2/en not_active Expired - Fee Related
-
2013
- 2013-09-11 US US14/024,354 patent/US8822457B2/en not_active Expired - Fee Related
-
2014
- 2014-09-29 HK HK14109767.6A patent/HK1196358A1/xx not_active IP Right Cessation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP10010709A (es) | Nuevas piridin-2-onas y piridazin-3-onas sustituidas | |
| ECSP10010384A (es) | Nuevas piridinonas y piridazinonas | |
| ECSP13012437A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| ECSP13013025A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| ECSP14013212A (es) | Inhibidores de la tirosina-quinasa de bruton | |
| PE20151336A1 (es) | Inhibidores de la tirosina-quinasa de bruton | |
| CO6680683A2 (es) | Inhibiddores de la prostaglandina e2 sintasa-1 microsómica (mpges-1) y composiciones que los contienen, útiles en el tratamiento de enfermedades inflamatorias | |
| UY29458A1 (es) | Heterociclos sustituidos y usos de los mismos | |
| NI201200190A (es) | Composiciones y métodos para modular la vía de señalización de wnt | |
| SV2010003556A (es) | Moleculas y metodos para modular el componente de complemento | |
| CR20140312A (es) | 4-fenil-piridinas sustiuidas para el tratamiento de enfermedades relacionadas con el receptor de nk1 | |
| PA8793301A1 (es) | Imidazoles bicíclicos fusionados | |
| SV2011003903A (es) | Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa iv para el tratamiento o prevencion de diabetes | |
| CR8497A (es) | Derivados de azepinoindol como agentes farmaceuticos | |
| CU23836B1 (es) | Compuestos 1,3-diona bicíclicos herbicidamente activos | |
| CL2011001295A1 (es) | Compuestos derivados de 1h-pirazol-4-carboxamida; metodo de control o prevencion de una infestacion de plantas utiles por microorganismos fitopatogenos; composicion pesticida que comprende a dichos compuestos. | |
| CO6270312A2 (es) | Moduladores de gpr40 bifenilo-sustituidos | |
| DOP2006000032A (es) | Compuestos de bis arilo y heteroarilo sustituidos como antagonistas selectivos de 5ht2a | |
| NI200900149A (es) | COMPUESTOS TRICÍCLICOS, COMPOSICIONES, Y PROCEDIMIENTOS. Caso: PC33715A | |
| ECSP088527A (es) | 3-aminociclopentanocarboxamidas como moduladores de receptores de quimioquinas | |
| BR112014030604A2 (pt) | composições e métodos para a limpeza, desinfecção e higienização de efluentes neutros | |
| ECSP088749A (es) | Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos | |
| UY31925A (es) | Isoquinolinas e isoquinolinonas sustituidas | |
| UY32168A (es) | Nuevas composiciones de compuestos heterociclicos nitrogenados antibacterianos con otros compuestos antibacterianos y su utilización como medicamentos | |
| DOP2008000089A (es) | 18-metil-19-nor-androst-4-en-17, 17-espiroeteres (18-metil-19-nor-20-espirox-4-en-3-onas), asi como preparaciones farmaceuticas que los contienen |